Multimorbidity in type 1 Gaucher disease patients under miglustat therapy

被引：0

作者：

Engay, Blanca Medrano ^{[1
]}

Roy, Ana ^{[2
]}

Atutxa, Koldo ^{[3
]}

Diaz-Morant, Vicente ^{[4
]}

Garcia-Frade, Javier ^{[5
]}

Hernandez-Martin, Roberto ^{[6
]}

Luno, Elisa ^{[7
]}

Noya, Soledad ^{[8
]}

de la Serna, Javier ^{[9
]}

Villalon, Lucia ^{[10
]}

Giraldo, Pilar ^{[11
]}

机构：

[1] Inst Invest Sanitaria Aragon, Zaragoza, Spain

[2] Fdn Espanola Estudio & Terapeut Enfermedad Gauche, Zaragoza, Spain

[3] Hosp Galdakao, Bilbao, Spain

[4] Hosp Serrania Ronda, Ronda, Spain

[5] Hosp Rio Hortega, Valladolid, Spain

[6] Hosp Virgen de la Concha, Zamora, Spain

[7] Hosp Univ Cent Asturias, Oviedo, Spain

[8] Hosp Teresa Herrera, La Coruna, Spain

[9] Hosp Univ Doce Octubre, Madrid, Spain

[10] Hosp Alcorcon, Madrid, Spain

[11] Ciber Enfermedades Raras, Zaragoza, Spain

来源：

MOLECULAR GENETICS AND METABOLISM | 2018年 / 123卷 / 02期

关键词：

D O I：

10.1016/j.ymgme.2017.12.245

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

236

引用

页码：S93 / S94

页数：2

共 50 条

[31] Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project
Giraldo, Pilar
Alfonso, Pilar
Atutxa, Koldo
Fernandez-Galan, Maria A.
Barez, Abelardo
Franco, Rafael
Alonso, Dora
Martin, Alejandro
Latre, Paz
Pocovi, Miguel
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (12): : 1771 - 1775
[32] Lipoprotein metabolism in type 1 Gaucher disease patients on enzyme therapy.
Pastores, GM
Berglund, L
Desnick, RJ
JOURNAL OF INVESTIGATIVE MEDICINE, 1996, 44 (03) : A225 - A225
[33] Health outcomes research study on patients with type 1 Gaucher disease under substrate reduction therapy (SRT)
Medrano Engay, Blanca
Roy, Ana
Atutxa, Koldo
Diaz-Morant, Vicente
Garcia-Frade, Javier
Hernandez-Martin, Roberto
Luno, Elisa
Noya, Soledad
de la Serna, Javier
Villalon, Lucia
Giraldo, Pilar
MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) : S94 - S94
[34] Neurochemical abnormalities in patients with type 1 Gaucher disease on standard of care therapy
Kartha, Reena, V
Joers, James
Terluk, Marcia R.
Travis, Abigail
Rudser, Kyle
Tuite, Paul J.
Weinreb, Neal J.
Jarnes, Jeanine R.
Cloyd, James C.
oz, Golin
JOURNAL OF INHERITED METABOLIC DISEASE, 2020, 43 (03) : 564 - 573
[35] Clinical benefits of miglustat on bone disease in adult type 1 Gaucher disease (GD1): A meta-analysis
Pastores, G. M.
Elstein, D.
Hrebicek, M.
Zimran, A.
CALCIFIED TISSUE INTERNATIONAL, 2007, 80 : S68 - S68
[36] Imino sugar therapy for type 1 Gaucher disease
Priestman, DA
Platt, FM
Dwek, RA
Butters, TD
GLYCOBIOLOGY, 2000, 10 (11) : IV - VI
[37] Home therapy for type 1 Gaucher disease in Spain
Calvo, JIP
Castellano, PG
MEDICINA CLINICA, 2002, 119 (19): : 756 - 756
[38] Encore! Oral therapy for type 1 Gaucher disease
Weinreb, Neal J.
BLOOD, 2017, 129 (17) : 2337 - 2338
[39] Evaluation of endocrinological involvement and metabolic status in patients with Gaucher disease Type 1 and Fabry disease under enzyme replacement therapy
Ersoy, Melike
Piskinpasa, Hamide
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2022, 35 (04): : 519 - 527
[40] A CLINICAL STUDY TO ASSESS MIGLUSTAT AS MAINTENANCE THERAPY FOR ADULT PATIENTS WITH STABLE TYPE 1 GAUCHER DISEASE (GD 1) AFTER SWITCH FROM ENZYME REPLACEMENT THERAPY (ERT): OBJECTIVES AND STUDY DESIGN
Ait-Aissa, N.
Jamieson, V
Morand, O.
Esparza, I
Goffin, H.
JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 : 170 - 170

← 1 2 3 4 5 →